Google Groups no longer supports new Usenet posts or subscriptions. Historical content remains viewable.
Dismiss
Targeted therapy in cancer
7 views
Skip to first unread message
marc.lacr...@gmail.com
Jul 12, 2014, 11:18:54 AM7/12/14
to
Targeted therapy in cancer
https://www.novapublishers.com/catalog/product_info.php?products_id=50896
Author: Marc Lacroix
Pub. Date: 2014 - 4th Quarter
Binding: Hardcover
https://www.novapublishers.com/catalog/product_info.php?products_id=50994
Authors: Marc Lacroix
Pub. Date: 2014
Binding: ebook
Abstract
Since the year 2000, exciting developments in cancer therapy have occurred. For decades in the 20th century, the hallmark of medical treatment for cancer had been cytotoxic chemotherapy, with drugs targeting rapidly dividing cells, including cancer cells but also certain normal tissues. As a result, many patients experienced the "classic" toxicities of alopecia, gastrointestinal symptoms and/or myelosuppression. In the last years, however, clinical research has been strongly occupied with the identification of mutations and aberrations concerning molecular pathways in cancer and their alterations, this has enabled the emergence of a "targeted" (somewhat personalized) medicine approach to treatment. Today, although traditional cytotoxic chemotherapy remains the treatment of choice for many malignancies, notably as first-line agents, targeted therapies are a possible choice for many types of cancer, including breast, prostate, CRC, lung, kidney cancers, as well as lymphoma, leukemia, and myeloma. More than 60 of these targeted therapies recently approved by the United States Food and Drug Administration (FDA) are detailed in the book, and their intended use in one or more cancer types are shown.
Table of contents
Preface
Chapter 1 Innovation in the biopharmaceutical pipeline
Chapter 2 The diversity of targeted cancer drugs
Chapter 3 Chronological list of targeted cancer drugs
Chapter 4 Targeted cancer drugs: detailed description
Targeted therapy for:
Chapter 5 chronic lymphocytic leukemia
(rituximab - alemtuzumab - ofatumumab - obinutuzumab - ibrutinib
Chapter 6 HER2-positive breast cancer
(trastuzumab - lapatinib - pertuzumab - ado-trastuzumab)
Chapter 7 metastatic breast cancer - varia
(ixabepilone - eribulin - everolimus)
Chapter 8 chronic myelogenous leukemia
(imatinib - nilotinib - dasatinib - bosutinib - ponatinib - omacetaxine)
Chapter 9 gastrointestinal stromal tumors
(imatinib - sunitinib - regorafenib)
Chapter 10 metastatic colorectal cancer
(bevacizumab - ziv-aflibercept - regorafenib - cetuximab - panitumumab)
Chapter 11 metastatic melanoma
(ipilimumab - vemurafenib - dabrafenib - trametinib)
Chapter 12 multiple myeloma
(thalidomide - lenalidomide - pomalidomide - bortezomib - carfilzomib)
Chapter 13 metastatic castration-resistant prostate cancer
(cabazitaxel - sipuleucel-T - abiraterone - denosumab - enzalutamide - radium Ra223)
Chapter 14 renal cell carcinoma
(sunitinib - pazopanib - bevacizumab - sorafenib - axitinib - temsirolimus - everolimus)
Chapter 15 gastric cancer
(trastuzumab - ramucirumab)
Chapter 16 non-small cell lung cancer
(pemetrexed - bevacizumab - gefitinib - erlotinib - afatinib)
Chapter 17 myelodysplastic syndromes
(azacitidine - decitabine - lenalidomide)
Chapter 18 mantle cell lymphoma
(bortezomib - lenalidomide - ibrutinib)
Chapter 19 Abbreviations
Chapter 20 Generic names - Trade names equivalences
Chapter 21
https://www.novapublishers.com/catalog/product_info.php?products_id=50896
Author: Marc Lacroix
Pub. Date: 2014 - 4th Quarter
Binding: Hardcover
https://www.novapublishers.com/catalog/product_info.php?products_id=50994
Authors: Marc Lacroix
Pub. Date: 2014
Binding: ebook
Abstract
Since the year 2000, exciting developments in cancer therapy have occurred. For decades in the 20th century, the hallmark of medical treatment for cancer had been cytotoxic chemotherapy, with drugs targeting rapidly dividing cells, including cancer cells but also certain normal tissues. As a result, many patients experienced the "classic" toxicities of alopecia, gastrointestinal symptoms and/or myelosuppression. In the last years, however, clinical research has been strongly occupied with the identification of mutations and aberrations concerning molecular pathways in cancer and their alterations, this has enabled the emergence of a "targeted" (somewhat personalized) medicine approach to treatment. Today, although traditional cytotoxic chemotherapy remains the treatment of choice for many malignancies, notably as first-line agents, targeted therapies are a possible choice for many types of cancer, including breast, prostate, CRC, lung, kidney cancers, as well as lymphoma, leukemia, and myeloma. More than 60 of these targeted therapies recently approved by the United States Food and Drug Administration (FDA) are detailed in the book, and their intended use in one or more cancer types are shown.
Table of contents
Preface
Chapter 1 Innovation in the biopharmaceutical pipeline
Chapter 2 The diversity of targeted cancer drugs
Chapter 3 Chronological list of targeted cancer drugs
Chapter 4 Targeted cancer drugs: detailed description
Targeted therapy for:
Chapter 5 chronic lymphocytic leukemia
(rituximab - alemtuzumab - ofatumumab - obinutuzumab - ibrutinib
Chapter 6 HER2-positive breast cancer
(trastuzumab - lapatinib - pertuzumab - ado-trastuzumab)
Chapter 7 metastatic breast cancer - varia
(ixabepilone - eribulin - everolimus)
Chapter 8 chronic myelogenous leukemia
(imatinib - nilotinib - dasatinib - bosutinib - ponatinib - omacetaxine)
Chapter 9 gastrointestinal stromal tumors
(imatinib - sunitinib - regorafenib)
Chapter 10 metastatic colorectal cancer
(bevacizumab - ziv-aflibercept - regorafenib - cetuximab - panitumumab)
Chapter 11 metastatic melanoma
(ipilimumab - vemurafenib - dabrafenib - trametinib)
Chapter 12 multiple myeloma
(thalidomide - lenalidomide - pomalidomide - bortezomib - carfilzomib)
Chapter 13 metastatic castration-resistant prostate cancer
(cabazitaxel - sipuleucel-T - abiraterone - denosumab - enzalutamide - radium Ra223)
Chapter 14 renal cell carcinoma
(sunitinib - pazopanib - bevacizumab - sorafenib - axitinib - temsirolimus - everolimus)
Chapter 15 gastric cancer
(trastuzumab - ramucirumab)
Chapter 16 non-small cell lung cancer
(pemetrexed - bevacizumab - gefitinib - erlotinib - afatinib)
Chapter 17 myelodysplastic syndromes
(azacitidine - decitabine - lenalidomide)
Chapter 18 mantle cell lymphoma
(bortezomib - lenalidomide - ibrutinib)
Chapter 19 Abbreviations
Chapter 20 Generic names - Trade names equivalences
Chapter 21
0 new messages